| ABSTRACT Objective::To observe the efficacy and safety of mirtazapine treatment of diarrhea predominant irritable bowel syndrome (D-IBS) of clinical. Methods::42 cases diagnosed as diarrhea predominant irritable bowel syndrome were orally given mirtazapine, from the starting dose of 10 mg per night, to 15 mg for the first 3 days and then to 30 mg in a week for 8 weeks. Before and after the treatment, their D IBS gastrointestinal symptoms, clinical efficacy of overall rating scale (CGI), Hamilton depression scale (HAMD) and Hamilton anxiety scale (HAMA) evaluation of curative effect were evaluated. The safety was evaluated by the adverse reaction scale (TESS). Results::The efficient rate of 39 cases observed for 8 weeks reached 97.4% at the end of 8 weeks. Their gastrointestinal symptoms, CGI, HAMD and HAMA scores were compared. There were more significant differences after the treatment than before it (P<0.05). The main adverse reactions as dizziness, drowsiness, fatigue appeared within 1 week, but they could be relieved by themselves. Conclusion::Mirtazapine could alleviate D IBS patients with gastrointestinal symptoms and improve the symptoms of anxiety and depression. It is a kind of safe and effective drug with clinical significance. |
